Michele Vonberg
Nurse Practitioner · Saginaw, MINPI 1578173514
Payments from drug & device makers
Across 95 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$235
- AstraZeneca$207
- AbbVie$179
- Otsuka America Pharmaceutical, Inc.$104
- GSK$101
- Lilly USA, LLC$89
- plus $946 from 23 others
What the payments were for
- Food & beverage$1,84799%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $235 |
| AstraZeneca | 9 | $207 |
| AbbVie | 9 | $179 |
| Otsuka America Pharmaceutical, Inc. | 5 | $104 |
| GSK | 6 | $101 |
| Lilly USA, LLC | 5 | $89 |
| Boehringer Ingelheim | 5 | $77 |
| Astellas Pharma US Inc | 3 | $73 |
| Vanda Pharmaceuticals Inc. | 3 | $73 |
| Pfizer | 4 | $72 |
| Axsome Therapeutics, Inc. | 4 | $70 |
| Organon | 3 | $54 |
| Bayer | 3 | $54 |
| Novartis | 2 | $48 |
| Exact Sciences | 3 | $44 |
| Cipher Pharmaceuticals US LLC | 1 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Merck | 2 | $37 |
| Amgen | 2 | $35 |
| Lundbeck LLC | 2 | $33 |
| Hologic Sales And Service, LLC | 1 | $26 |
| Boston Scientific | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Johnson & Johnson | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
How this compares
$1,861 in reported general payments places this provider in the 85th percentile of 3,351 nurse practitioner providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 198 | $177,820 |
| TrulicityDulaglutide | 176 | $174,726 |
| JardianceEmpagliflozin | 113 | $114,251 |
| OzempicSemaglutide | 90 | $106,373 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $85,336 |
| EliquisApixaban | 54 | $38,232 |
| JanuviaSitagliptin Phosphate | 46 | $36,341 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $20,222 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $11,146 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $9,174 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 18 | $7,767 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $6,538 |
| Novolog FlexpenInsulin Aspart | 30 | $6,453 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 189 | $5,768 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $4,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Bevespi Aerosphere | $207 | $185,587216 claims |
| Lilly USA, LLCTrulicity | $89 | $174,726176 claims |
| Boehringer IngelheimJardiance | $77 | $114,251113 claims |
| Novo NordiskOzempic | $235 | $106,37390 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta, Shingrix | $101 | $102,407186 claims |
| PfizerEliquis | $72 | $38,23254 claims |
| MerckJanuvia | $37 | $36,34146 claims |
| Sanofi-aventis U.S. LLCLantus | $23 | $1,38613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Saginaw
- Jessica HerekSaginaw$13K
- Davida KrugerDetroit$1.8M
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Abubakir BabanDearborn$143K
- Elizabeth KirshnerAnn Arbor$119K
- Lisa Astalos ChismWoodhaven$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.